# Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

> **NCT00006669** · PHASE2 · WITHDRAWN · sponsor: **Medstar Health Research Institute**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** sargramostim
- **DRUG:** EPOCH regimen
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00006669
- **Lead sponsor:** Medstar Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1999-09
- **Primary completion:** 2000-01
- **Final completion:** 2000-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006669, "Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*